The Psychology of Fraud, Episode 3: Big Challenges of Fraud in the C Suite

Video

In the third episode of this series, experts weigh in on the impact of fraud at the executive level.

Senior executives are in a unique position to commit fraud that can cost their organizations significant amounts of money. In this third episode, the experts discuss why and how executives are able to commit fraud at such significant levels, as well as the impact of executive fraud on organizations and well beyond.

See “The Psychology of Fraud, Episode 1: Myths and Misconceptions” here.

See “The Psychology of Fraud, Episode 2: The Shark, the Lark, and the Mark: Why Do People Commit Fraud?” here.

Mr Bigelow is president of The Bigelow Consulting Group, Inc. He also functions as the vice president—strategy, marketing, and communications for The Behavioral Forensics Group™ LLC, a consulting firm that treats fraud as a human act and explores the psychology of fraud.

Dr Morrison is a clinical assistant professor of psychiatry at Rosalind Franklin University’s Chicago School of Medicine, and past president of the Academy of Organizational and Occupational Psychiatry. He is also a member of the Group for the Advancement of Psychiatry (GAP)–Committee on Work & Organizations; Institute for Fraud Prevention (IFP); Tomkins Institute of Applied Studies of Motivation, Emotion and Cognition. He is a co-author of A.B.C.’s of Behavioral Forensics and Psychiatry of Workplace Dysfunction, and a regular contributor to the B4G™ blog, bringingfreudtofraud.com.

Dr Ramamoorti is currently an associate professor of accounting at the University of Dayton and the managing principal and CEO of The Behavioral Forensics Group™ LLC. He is also a regular contributor to the B4G™ blog, bringingfreudtofraud.com.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.